Education
About Us
Working with TipRanks
Follow Us
Genmab A/S (GB:0MGB)
:0MGB
0MGB Stock Chart & Stats
Day’s Range― - ―
52-Week Rangekr1,168.50 - kr1,892.00
Previous CloseN/A
Volume5.49K
Average Volume (3M)14.42K
Market Cap
kr84.70B
Enterprise Valuekr64.38B
Total Cash (Recent Filing)kr3.23B
Total Debt (Recent Filing)kr143.00M
Price to Earnings (P/E)11.4
Beta0.94
Next Earnings
Nov 06, 2025EPS Estimate
28.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)34.70
Shares Outstanding64,154,250
10 Day Avg. Volume17,845
30 Day Avg. Volume14,419
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr1,988.43Price Target Upside43.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Sales Guidance And GrowthGenmab has provided peak sales guidance for key assets, showing improved visibility on growth through strategic developments.
Valuation And Growth OpportunitiesGenmab's market value and strategic pipeline developments offer potential for increased investor confidence and growth opportunities.
Bears Say
Downgrade And UnderperformanceThe recent disappointing ‘Hexabody’ pipeline news has led to a downgrade of Genmab's stock to underperform.
Patent Expiration ConcernsAnalyst's regression analysis suggests that the share price does not fully account for the loss of exclusivity of Darzalex, which could significantly impact future revenues.
Genmab A/S News
0MGB FAQ
What was Genmab A/S’s price range in the past 12 months?
Genmab A/S lowest share price was kr1168.50 and its highest was kr1892.00 in the past 12 months.
What is Genmab A/S’s market cap?
Genmab A/S’s market cap is kr84.70B.
When is Genmab A/S’s upcoming earnings report date?
Genmab A/S’s upcoming earnings report date is Nov 06, 2025 which is in 90 days.
How were Genmab A/S’s earnings last quarter?
Genmab A/S released its earnings results on Aug 07, 2025. The company reported kr34.698 earnings per share for the quarter, beating the consensus estimate of kr25.562 by kr9.135.
Is Genmab A/S overvalued?
According to Wall Street analysts Genmab A/S’s price is currently Undervalued.
Does Genmab A/S pay dividends?
Genmab A/S does not currently pay dividends.
What is Genmab A/S’s EPS estimate?
Genmab A/S’s EPS estimate is 28.01.
How many shares outstanding does Genmab A/S have?
Genmab A/S has 64,154,250 shares outstanding.
What happened to Genmab A/S’s price movement after its last earnings report?
Genmab A/S reported an EPS of kr34.698 in its last earnings report, beating expectations of kr25.562. Following the earnings report the stock price went down -3.64%.
Which hedge fund is a major shareholder of Genmab A/S?
Currently, no hedge funds are holding shares in GB:0MGB
Company Description
Genmab A/S
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company also develops Teclistamab, which is in Phase 2 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
0MGB Stock 12 Month Forecast
Average Price Target
kr1,988.43
▲(43.35% Upside)
Technical Analysis
Ownership Overview
―
Insiders
11.63%
Mutual Funds
<0.01% Other Institutional Investors
79.56% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---